Transforming the care of hypertrophic cardiomyopathy and related conditions.
We seek to deliver better outcomes and quality of life for patients.
Our Focus
01
About Hypertrophic Cardiomyopathy
About Hypertrophic Cardiomyopathy
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is among the most common rare diseases, affecting approximately 1 in 500 individuals in the United States.
In HCM, the heart muscle becomes abnormally thickened, causing inefficient pumping and filling of blood. This can lead to symptoms such as shortness of breath, chest pain, fatigue, and fainting.
02
About BHB-1893
About BHB-1893
About BHB-1893
BHB-1893 is a selective, small-molecule cardiac myosin inhibitor engineered to improve heart performance in patients with HCM.
03
Pipeline
Pipeline
Pipeline
We are advancing BHB-1893, our investigational HCM treatment, through global late-stage clinical development.
News & Updates
Interested in joining our team?
Learn more about our openings.